AI-Assisted Grading of Prostate Biopsies Using Deep Learning

Singapore, April 30, 2024 — Qritive participated in the USCAP 113th Annual Meeting with multiple studies demonstrating the clinical value of AI-powered pathology applications in cancer diagnostics.

A Deep Learning Algorithm to Help Identify and Grade Tumor into ISUP Grade Groups on Prostate Needle Biopsies

USCAP 113th Annual Meeting | March 23–28, 2024 | Baltimore, MD

This study presents the development and clinical validation of a deep learning algorithm designed to assist in the identification and grading of prostate adenocarcinoma on needle biopsy slides, following ISUP Grade Group classifications.

The model was trained on thousands of annotated samples and demonstrated strong alignment with diagnostic consensus. By integrating this AI module into pathology workflows, clinicians can benefit from enhanced consistency, improved efficiency, and increased confidence in diagnostic decision-making—while maintaining the pathologist’s role in final evaluation.

View Abstract on USCAP Website

About Qritive

Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.

By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.

Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com